In these studies, Compound 182 and ABBV-484 were able to promote diverse tumor eradication either alone or in combination with anti-PD1, through diverse immune mechanisms involving T cells, NK cells, and tumor intrinsic sensitization to interferon induced dead. The gene discussed is PDCD1; the disease is neoplasm.